The extension signals that Monro's strategic review is ongoing and the board wants to prevent any hostile bid during the process. Monitor for any announcement of a sale, merger, or other transaction resulting from the review.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $11.31entry
- T+1 · 11d ago −3.18%α −3.50% · $10.95
- T+5 · 5d ago −8.44%α −11.73% · $10.36
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Monro extended its shareholder rights plan (poison pill) by one year, from November 6, 2026 to November 1, 2027, to support an ongoing review of strategic alternatives. The extension preserves the board's ability to conduct the review without the risk of an unsolicited takeover.
Key Facts
- Rights Agreement final expiration extended from November 6, 2026 to November 1, 2027.
- Extension approved by Board to support ongoing review of strategic alternatives.
- Rights are redeemable at $0.01 per Right at the Company's option.
- Purchase price per one one-thousandth of a share of Preferred Stock is $90.00.
Financial Impact
No direct financial impact; extension of a defensive measure with no stated monetary value.
Risk Factors
- The poison pill extension could deter potential acquirers and reduce the likelihood of a premium takeover bid.
- If the strategic review concludes without a transaction, the extension may be viewed as entrenchment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-447246 |
| Document: d459293dex42.htm | 0001193125-26-447246 |
| Document: 0001193125-26-447246-index-headers.html | 0001193125-26-447246 |
| Document: 0001193125-26-447246-index.html | 0001193125-26-447246 |
| Document: 0001193125-26-447246.txt | 0001193125-26-447246 |
Track record
8 reports on MNRO
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +8.05% at T+5 after the Oct 29, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.36 Now $10.53 +1.64% settles Dec 15
- Nov 4, 202612d ago 8-K Neutral 3/10 Viewing Entry $11.31 Now $10.53 −6.90% settles Dec 4
- Oct 29, 202618d ago 8-K Bearish 5/10 Entry $12.30 Now $10.53 +14.39% settles Nov 27
- Aug 13, 202613w ago 8-K Neutral 2/10 Entry $11.27 to $12.79 Now $10.53 −6.57% ▲ +13.49% +15.23% vs SPY
- Jul 29, 202615w ago 8-K Bearish 6/10 Entry $13.26 to $12.61 Now $10.53 +20.56% ▲ +4.87% +9.89% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $16.00 to $17.33 Now $10.53 −34.19% ▲ +8.31% +8.11% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bullish 5/10 Entry $16.08 to $16.83 Now $10.53 −34.51% ▲ +4.66% +2.77% vs SPY
- May 27, 202624w ago 8-K Bullish 7/10 Entry $15.93 to $16.05 Now $10.53 −33.90% ▲ +0.75% +2.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers